Drugs / [Lu-177]-PNT2002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04647526 | Feb 2021 → Nov 2023 overdue | castration-resistant prostate carcinoma | POINT Biopharma | Active not recruiting | Met primary |
| Phase not stated1 trial | ||||||
| — | NCT06033001 | — | castration-resistant prostate carcinoma | Lantheus Medical Imaging | Temporarily not available | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [Lu-177]-PNT2002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04647526 ↗ |
| Known as | [177Lu]Lu-PNT2002 | “INTRODUCTION: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [177Lu]Lu-PNT2002 radioligand therapy in metastatic...” PMID 39839782 ↗ Jan 2025 |
| Action | Deplete | “delivers radiation to your cancer by binding to the PSMA which helps destroy the cancer cells” NCT06033001 ↗ |
| Modality | Other / unclassified | “radioligand therapy” PMID 39839782 ↗ Jan 2025 |
| Route | Intravenous | “intravenously” PMID 39839782 ↗ Jan 2025 |